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Objectives. Anti-TNF therapy has improved outcomes for patients with highly active RA. Less is known about its effectiveness in patients
with lower disease activity. The aim of this analysis is to compare the response to anti-TNF therapy between RA patients with high
(DAS28>5.1) and moderate (DAS28>3.2–5.1) disease activity.
Methods. A total of 4687 anti-TNF and 344 DMARD patients with high disease activity despite treatment with two standard DMARDs
(including MTX) and 224 anti-TNF- and 300 DMARD-treated patients with moderate disease activity were selected from the British
Society For Rheumatology Biologics Register. Mean change in HAQ over the first 12 months of enrolment was compared first between
anti-TNF-treated and untreated patients in each DAS28 group, and then between anti-TNF-treated patients in the moderate and high DAS28
groups, using doubly robust estimates, adjusting for age, gender, disease duration, baseline HAQ and DAS28 score, number of previous
DMARDs and steroid use.
Results. Compared with anti-TNF-untreated patients within each DAS group, treated patients were younger, had higher DAS28 and HAQ
and had failed a higher number of previous DMARDs. The mean adjusted change in HAQ over 12 months was similar in anti-TNF-treated
patients with moderate and high disease activity at baseline: moderate  0.26 (95% CI  0.35,  0.16), high  0.28 (95% CI  0.34,  0.23) and
mean difference  0.03 (95% CI  0.14, 0.08).
Conclusions. Improvement in HAQ score 12 months after start of anti-TNF therapy was not dependent on baseline DAS28 scores,
suggesting that substantial benefits may also be gained by treating those with moderately active disease despite standard DMARD therapy.
KEY WORDS: Rheumatoid arthritis, Anti-TNF, DMARDs, Disease activity, Disability, Treatment outcome.
Introduction
The anti-TNF therapies, developed against the background of an
increasing understanding of the pathogenesis of RA, represent
a tremendous advance in the management of RA. Their use has
added to the confidence of healthcare professionals and patients
that disease previously resistant to conventional DMARDs can
usually be satisfactorily controlled, and remission of disease is an
increasingly realistic aim. However, these therapies are expensive
in comparison with conventional DMARDs and, in countries with
socialized healthcare, their unrestricted use would be unafford-
able. In the UK, eligibility criteria for the use of these agents
have been issued by the British Society for Rheumatology and
the National Institute for Health and Clinical Excellence
(NICE) [1]. The current guidelines for initiation of anti-TNF
agents in patients with RA suggest that a patient should have a
28-joint count disease activity score (DAS28) >5.1 [2] on two
occasions at least 1 month apart despite adequate previous treat-
ment with at least two DMARDs, one of which should have been
MTX. Adequate treatment is defined as a therapeutic course of at
least 6 months unless side effects are experienced.
In recent years, there has been a shift towards the early
aggressive treatment of RA, with a goal of low disease activity.
The Tight Control of Rheumatoid Arthritis (TICORA) study
found that early aggressive therapy in RA, with a goal DAS
<2.4, resulted in better clinical and radiographic outcomes [3].
Similarly, the recent BeSt (a Dutch acronym for Behandel-
Strategiee, or ‘treatment strategies’) study, which randomized
patients with early RA to one of the four treatment strategies,
found the best outcomes in those regimes with a rapid reduction
and maintenance of disease activity below a DAS of 2.4 [4].
Follow-up from this same study found that the efficacy of
subsequent standard DMARD treatment after initial failure
with MTX (defined as failure to reduce DAS <2.4 or toxicity)
was limited, with many patients subsequently requiring anti-
TNF therapy to bring the disease under control [5]. Control of
disease activity to very low levels in RA has also been shown to
significantly reduce work disability in patients with early RA [6].
The use of standard DMARD therapy alone will result in a
proportion of patients with ongoing moderate disease activity.
There are, however, limited data on the effectiveness of anti-
TNF therapies in patients with moderate disease activity,
compared with those with high disease activity. A number of
studies [7–10] have found that patients who start anti-TNF ther-
apy with lower DAS28 scores are more likely to achieve disease
remission, defined using a DAS28<2.6, but less likely to reach
a 50 or 70% improvement in disease activity, defined using the
ACR response criteria [11]. The results of these studies are intui-
tive as it is likely easier to reach a very low DAS28 score if one
starts with lower disease activity, whereas those with high DAS28
are more likely to experience larger percentage of improvements
due to regression to the mean.
Many health economic models in RA are based on the HAQ,
a widely used patient reported outcome measure of physical
function [12]. HAQ scores are also important predictors of other
clinical outcomes, such as future work disability [13] and mortality
[14]. There are no previous studies specifically looking at the influ-
ence of anti-TNF therapy on HAQ in RA patients with moderate
disease activity. Therefore, using data from patients enrolled
in the British Society for Rheumatology Biologics Register
(BSRBR), this analysis compares the response to anti-TNF ther-
apy, defined using absolute change in HAQ score over a 12-month
period, first between anti-TNF-treated and -untreated patients
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least two standard DMARDs, including MTX, and second,
between anti-TNF-treated patients with moderate and high
disease activity at the start of therapy.
Methods
Patient population
Patients for this study were selected from the BSRBR. This study,
established in October 2001, has been systematically following
patients from start of anti-TNF therapies for RA. Details of
this study have been published elsewhere [15]. A parallel com-
parison arm of patients receiving DMARD therapy is also being
recruited. The study was approved by the North West Multicentre
Research Ethics Committee, and all subjects gave their written
consent for participation.
Baseline data collection
Anti-TNF cohort. Patients with no previous exposure to biolo-
gic agents who were starting one of the three available anti-TNF
agents (etanercept, infliximab or adalimumab) in any hospital
throughout the UK were eligible to be registered at the start of
anti-TNF therapy. Their rheumatology consultant or clinical
nurse specialist completed a baseline form that includes demo-
graphic details, diagnosis, current and past anti-rheumatic therapy
and DAS28 at the time the first anti-TNF therapy was started.
In addition, the patient was asked to complete the UK version of
the HAQ [16]. All data were collected centrally at the University
of Manchester.
DMARD cohort. Twenty-five hospitals across the UK were
designated as control centres (see Appendix 1). Control patients
were selected if they had RA, were receiving a DMARD, had no
history of exposure to biologic therapies and were felt to have
active disease (a guide DAS28 of at least 4.2 was provided
although patients may have had lesser disease activity). Data
collection was identical to that of the anti-TNF cohort with the
exception of the HAQ, which was posted directly to the patient’s
home for completion and return by post.
Follow-up data collection. Follow-up data collection is identical
for both cohorts and is ongoing for the larger study. On a
6-monthly basis for 3 years and then annually thereafter, hospitals
are contacted for updated information on disease activity, changes
to anti-rheumatic therapy and the development of any adverse
events. All patients (anti-TNF and DMARD) are posted a HAQ
to their homes for completion and return to the University of
Manchester by post.
Data analysis. The primary outcome of this analysis was change
in HAQ score over the first 12 months of anti-TNF therapy or the
first 12 months of observation (for DMARD controls). Patients in
the anti-TNF cohort were included if they had been registered
within 90 days of starting their first anti-TNF therapy, had
failed at least two DMARDs, had a DAS28 recorded at baseline
and had completed a baseline and 12-month HAQ. The 90-day
cut-off was chosen to ensure that the 12-month follow-up ques-
tionnaires were completed as close as possible to 1 year after
starting the anti-TNF therapy, yet allow time for baseline forms
to be completed by the recruiting hospitals. Patients were selected
from the DMARD control cohort for analysis if they had received
therapy with at least two DMARDs, one of which must have been
MTX. For patients in the control group who had only ever
received two DMARDs, they must have been receiving the
second DMARD for at least 6 months. Similarly, patients
needed to have a DAS28 recorded at baseline and have completed
a baseline and 12-month HAQ. All patients were subsequently
divided into two groups based on baseline DAS28 score (mod-
erate: >3.2–5.1 and high: >5.1). Baseline characteristics were
compared using non-parametric descriptive statistics. Response
(change in HAQ over 12 months) was modelled using doubly
robust estimation. This technique, developed by Bang and
Robins [17], aims to combine the advantages of regression model-
ling and inverse probability of treatment weighting (IPTW) [18].
Regression modelling fits a model for the outcome with treatment
as a predictor, and adjusts for imbalances in covariates between
the treated and untreated by including these covariates in the out-
come model. IPTW modelling uses the covariates in a logistic
regression model to predict the probability of receiving treatment,
and by weighting by the inverse of the probability of receiving
treatment, produces a pseudopopulation in which the covariates
are no longer confounders. Both of these methods should produce
unbiased estimates if the assumptions of the methods are met,
namely that the outcome model is correctly specified for regres-
sion modelling and that the probability of treatment is correctly
specified for the IPTW model. The doubly robust model will
produce an unbiased estimate if either of the two models is
specified correctly. The analysis was performed using the Stata
command dr [19]. The following baseline covariates were entered
into the models: age, gender, disease duration, baseline HAQ,
baseline DAS28, previous number of DMARDs and current use
of steroids (yes/no). Results are presented as the adjusted mean
change in HAQ with 95% CIs. The response was first compared
between anti-TNF and DMARD patients within each DAS28
group, and then the response was compared between anti-TNF
patients with moderate and high disease activity.
Results
Study population
Until 13 December 2007, 8448 anti-TNF patients had started
their first anti-TNF within 90 days of registration, had failed
two previous DMARDs, including MTX, and had a baseline
HAQ and DAS28 recorded. Of these, 6935 patients had reached
12 months of follow-up and 4922 had completed a 12-month
HAQ (71%): 224 (4.6%) had moderate disease and 4687
(95.2%) had high disease activity at baseline, in keeping with
national guidelines. Eleven patients had a DAS28 43.2 recorded
at the start of therapy and were excluded from the analysis.
To the same date, 1675 DMARD control patients had been
registered with the BSRBR who had received treatment with at
least two DMARDs, including MTX. Of these, a baseline HAQ
and DAS28 was available for 1300 (78%). A total of 1010 patients
had reached 12 months of follow-up and 720 had completed a
12-month HAQ (71%): 300 (42%) had moderate disease and
344 (47%) had a DAS28 >5.1. The remaining patients had low
disease activity at baseline and were excluded from the analysis.
Baseline characteristics
Baseline characteristics are summarized in Table 1. All groups
were similar with respect to gender and disease duration, but
patients in the DMARD cohort tended to be slightly older than
patients who were started on anti-TNF (63 vs 57, P<0.001 in the
moderate DAS28 group and 60 vs 58, P<0.001 in the high
DAS28 group). Patients who received anti-TNF therapy tended
towards higher disease activity, demonstrated with higher swollen
and tender joint counts. ESRs were similar between anti-TNF-
treated and -untreated cohorts in both DAS28 groups, but there
was a significantly higher proportion of anti-TNF-treated patients
who were receiving corticosteroids. Similarly, patients who had
received anti-TNF, regardless of baseline DAS28, had failed a
higher number of previous DMARDs.
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For both the DMARD and the anti-TNF cohorts, the baseline
HAQ score was higher in those patients in the high DAS28 group
(Table 2). Within each DAS28 group, the HAQ score was signifi-
cantly higher in those patients who received anti-TNF therapy.
However, treatment with anti-TNF therapy resulted in similar
reductions in HAQ score in both DAS28 groups when compared
with the untreated group [adjusted mean improvement  0.26
(95% CI  0.35,  0.16) in the moderate DAS28 group and
 0.28 (95% CI  0.34,  0.23) in the high DAS28 group]. The
difference in improvement in HAQ score between the moderate
and high DAS28 anti-TNF-treated groups was not statistically
significant [mean difference  0.03 (95% CI  0.14, 0.08)]. In addi-
tion, a similar proportion of patients in each anti-TNF-treated
group had an improvement in HAQ score in excess of the
minimally clinically important difference (MCID) of 0.22U [20]
(moderate DAS28 group: 53% and high DAS28 group: 58%,
P¼0.14) (Table 2). The main driver for the difference in improve-
ment between anti-TNF and DMARD controls in both DAS28
groups appeared to be the improvement gained in the anti-TNF
group, with no progression or improvement in HAQ seen over
12 months in the DMARD control group in either the moderate
or the high DAS28 group.
Concern has been raised that the DAS28 may not adequately
reflect disease activity in certain patients and can be raised by a
high number of tender joints and high patient global assessment in
the absence of swollen joints. There were differences in the
proportion of patients with less than three swollen joints in
the four treatment groups (moderate DAS28: DMARD 40%,
anti-TNF 25%, P<0.001; high DAS28: DMARD 11%, anti-
TNF 4%, P<0.001). However, total number of swollen joints
was not found to be associated with change in HAQ score
in the regression model for either the moderate DAS28 group
[ -coefficient  0.004 per joint (95% CI  0.013, 0.006)] or the
high DAS28 group [ -coefficient  0.0004 per joint (95% CI
 0.003, 0.002)].
Discussion
The results of this study have shown that treatment with anti-TNF
therapy is effective both in patients with high and moderate
disease activity. In addition, the magnitude of improvement in
both of these groups is similar, with a mean improvement in
HAQ score in excess of a minimally clinically important improve-
ment (>0.22) [20].
This study is not a clinical trial but rather an observational
study of real-world treatment response among patients in the
UK, and therefore, does have some limitations which must be
considered. As treatment was not assigned randomly to patients,
statistical models were used to account for differences in baseline
disease severity. These are dependent on the covariates entered
into the model and therefore, we cannot exclude the effects of
unmeasured confounding. Missing data may also have influenced
the results. Up to 25% of the patients did not return their HAQ
score at 1 year. In general, in both treated and untreated patients,
those who returned their forms were slightly older (DMARD: 61
vs 59 years, P¼0.05; anti-TNF: 57 vs 55 years, P¼0.001) and had
TABLE 2. HAQ score at baseline and 12 months
Baseline DAS28 >3.2–5.1 >5.1
Treatment group DMARD Anti-TNF DMARD Anti-TNF
n 300 224 344 4687
HAQ baseline, mean  S.D. 1.43 0.76 1.78 0.61 1.87 0.63 2.05 0.55
HAQ 12 months, mean   S.D. 1.45 0.78 1.51 0.75 1.85 0.63 1.71 0.72
Patients with >0.22 improvement in HAQ score at
12 months, n (%)
72 (24) 119 (53) 93 (27) 2725 (58)
Mean change in HAQ, 95% CI 0.03 ( 0.02, 0.07)  0.27 ( 0.34,  0.21)  0.01 ( 0.06, 0.03)  0.35 ( 0.36,  0.33)
Unadjusted mean change in HAQ (95% CI)
(anti-TNF vs DMARDs)
Reference  0.30 ( 0.38,  0.22) Reference  0.33 ( 0.40,  0.29)
Unadjusted mean difference in HAQ change
between moderate and high DAS, 95% CI
(anti-TNF only)
Reference  0.03 ( 0.12, 0.06)
Adjusted mean change in HAQ (95% CI)
(anti-TNF vs DMARDs)
Reference  0.26 ( 0.35,  0.16) Reference  0.28 ( 0.34,  0.23)
Adjusted mean difference in HAQ change between
moderate and high DAS (95% CI) (anti-TNF only)
Reference  0.03 ( 0.14, 0.08)
TABLE 1. Baseline characteristics in patients according to baseline DAS28 group and treatment group
Baseline DAS28 group >3.2–5.1 >5.1
Treatment group DMARD Anti-TNF P-value DMARD Anti-TNF P-value
n 300 224 344 4687
Age, years 63 (56–69) 57 (49–64) <0.001 60 (54–69) 58 (50–65) <0.001
Female, n (%) 229 (76) 162 (72) 0.297 276 (80) 3612 (77) 0.176
Disease duration, years 13 (7–21) 12 (7–21) 0.423 11 (5–21) 11 (6–19) 0.876
DAS28 score 4.33 (3.84–4.68) 4.74 (4.29–4.96) <0.001 5.93 (5.49–6.61) 6.65 (6.01–7.31) <0.001
28 swollen joint count 3 (1–5) 5 (3–9) <0.001 7 (4–10) 11 (7–16) <0.001
28 tender joint count 4 (2–6) 5 (2–8) 0.002 12 (8–18) 16 (11–22) <0.001
ESR, mm/h 21 (12–36) 21 (12–32) 0.363 39 (25–57) 42 (26–65) 0.048
CRP, mg/l 16 (8–33) 19 (9–39) 0.287 25 (12–46) 34 (17–66) 0.003
Patient global assessment (100-mm VAS) 46 (27–60) 50 (32–70) 0.010 70 (50–80) 75 (64–87) <0.001
Receiving oral steroids, n (%) 73 (24) 114 (51) <0.001 86 (25) 2147 (46) <0.001
No. of DMARDs (previous) 3 (2–4) 4 (3–5) <0.001 3 (3–4) 4 (3–5) 0.001
Values are given as median (interquartile range) unless otherwise specified.
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P¼0.008; anti-TNF: 13.6 vs 12.7, P¼0.001). Among untreated
patients, those who did not return their forms tended towards high
HAQ scores at baseline (1.6 vs 1.4, P¼0.005) although in the
treated group, there was no association between baseline
HAQ score and form return rate (2.05 in both groups).
Therefore, there is a possibility that we have over- or underesti-
mated the improvement in HAQ in either DAS28 groups.
In the UK, there are national guidelines which restrict the use
of anti-TNF therapies to those patients with a high DAS28.
Despite these guidelines, there was a group of patients who
received these therapies with a DAS28<5.1. It is possible that
these patients are fundamentally different from patients who
receive these agents in countries without these restrictions, mean-
ing the results may not be generalizable to a wider population.
There is also a possibility that these patients did have a high
DAS28 score at one point prior to treatment with anti-TNF,
but while waiting for therapy to begin, patients experienced a
drop in their DAS28 due to either natural variation in disease
activity or another intervention (e.g. i.m. steroid injection).
A review of the notes of patients from two centres suggests that
i.m. steroids had been administered a few weeks before the assess-
ment in up to 50% of the patients. However, a generally lower
HAQ score at the start of therapy in patients with moderate
disease activity compared with those patients with high DAS28
suggests that these patients did have lower disease activity. They
were also more likely to be already receiving oral steroids and to
have failed a higher number of previous DMARDs. Therefore,
the physician may have felt that anti-TNF therapy was the next
best therapy for these patients, regardless of their DAS28.
Similarly, we observed a cohort of patients that should have
been eligible for anti-TNF therapies according to DAS28 who did
not receive these therapies. Again, a long wait for treatment in
some areas (at times many months) may have resulted in these
patients being registered in the control arm of this study, although
over the course of the first year, only two patients in the moderate
DAS28 group and 11 patients in the high DAS28 group received
anti-TNF therapy. Exclusion of these patients from the analysis
did not alter the results. There may also have been other
unmeasured factors, such as general frailty or other medical
contraindications of treatment, which were not recorded by the
register which may also have influenced the physician’s choice of
treatment.
The patients in this study were analysed according to baseline
DAS28. However, the DAS28 itself is not without its limitations
and the treating physicians may have made treatment decisions
independent of DAS28 in certain patients. The DAS28 has a
strong weighting towards tender joint count and patient global
assessment, two relatively subjective measures of disease activity.
Indeed, studies have found that patients without inflammatory
arthritis but significant FM can also score high on the DAS28
[21]. Therefore, certain patients with high disease activity may
not have, in the physician’s opinion, had disease activity high
enough to warrant anti-TNF therapy. The DAS28 also excludes
certain joints, including the hips, ankles and feet, which may have
been important factors in deciding on therapy in individual cases.
Therefore, the DAS28 may not capture the full degree of disease
activity in the patient.
Despite these limitations, the observed improvements in HAQ
score were in the same range as those seen in randomized clinical
trials of anti-TNF therapies for MTX-resistant disease, which
ranged from an improvement of 0.15 up to 0.6U [22–27] with
the vast majority showing a net improvement in the range of 0.3
when placebo response was considered. Patients in our DMARD
group should be considered as routine care and no specific direc-
tion was given to try and reduce the disease activity below a
certain level. It is interesting to note that within this group, the
mean HAQ score did not change and only 25% of this group
experienced an improvement in excess of the MCID in HAQ
score, compared with >50% in the treated groups.
In conclusion, the results of this study indicate that the effec-
tiveness of anti-TNF therapy in improving the level of disability
among patients with severe DMARD-resistant RA appears to be
independent of baseline DAS28 score. Therefore, patients with
ongoing moderate disease activity despite treatment with
DMARDs may also benefit from biologic therapy. The results
of this study also indicate that anti-TNF therapy for those with
moderate DAS28 may be just as cost effective as treatment of
those with higher DAS28 scores, especially when assessed in
health economic models which are based on changes in HAQ [12].
Rheumatology key messages
  Anti-TNF agents significantly improve disability in patients with
persistent disease activity despite standard DMARDs.
  The influence of anti-TNF therapy on disability is independent of
baseline disease activity level.
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The BSRBR Control Centre Consortium consists of the following
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(Dr Nicola Maiden); Cannock Chase Hospital, Cannock Chase
(Dr Tom Price); Christchurch Hospital, Christchurch (Dr Neil
Hopkinson); Derbyshire Royal Infirmary, Derby (Dr Sheila
O’Reilly); Dewsbury and District Hospital, Dewsbury
(Dr Lesley Hordon); Freeman Hospital, Newcastle-upon-Tyne
(Dr Ian Griffiths); Gartnavel General Hospital, Glasgow (Dr
Duncan Porter); Glasgow Royal Infirmary, Glasgow (Prof.
Hilary Capell); Haywood Hospital, Stoke-on-Trent (Dr Andy
Hassell); Hope Hospital, Salford (Dr Romela Benitha); King’s
College Hospital, London (Dr Ernest Choy); Kings Mill Centre,
Sutton-In Ashfield (Dr David Walsh); Leeds General Infirmary,
Leeds (Prof. Paul Emery); Macclesfield District General Hospital,
Macclesfield (Dr Susan Knight); Manchester Royal Infirmary,
Manchester (Dr Ian Bruce); Musgrave Park Hospital, Belfast
(Dr Allister Taggart); Norfolk and Norwich University
Hospital, Norwich (Prof. David Scott); Poole General Hospital,
Poole (Dr Paul Thompson); Queen Alexandra Hospital,
Portsmouth (Dr Fiona McCrae); Royal Glamorgan
Hospital, Glamorgan (Dr Rhian Goodfellow); Russells Hall
Hospital, Dudley (Prof. George Kitas); Selly Oak Hospital, Selly
Oak (Dr Ronald Jubb); St Helens Hospital, St Helens (Dr Rikki
Abernethy); Weston General Hospital, Weston-super-Mare
(Dr Shane Clarke/Dr Sandra Green); Withington Hospital,
Manchester (Dr Paul Sanders); Withybush General Hospital,
Haverfordwest (Dr Amanda Coulson); North Manchester
General Hospital (Dr Bev Harrison); Royal Lancaster Infirmary
(Dr Marwan Bukhari); and The Royal Oldham Hospital (Dr Peter
Klimiuk).
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